Highlights Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Delayed Japan Exchange Other stock markets 22:30:00 2024-05-08 EDT			5-day change	1st Jan Change
5,245 ^JPY	-0.83%		-4.67%	+35.46%

05-07	Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	RE
05-07	Japan's Nikkei climbs on Fed rate-cut outlook, tech boost	RE

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	05-07	RE
Remsons, Daiichi Infotainments Form Joint Venture	04-30	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	04-29	MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	04-29	CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	04-29	AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	04-29	MT
Hipgnosis Songs Fund backs new Blackstone bid	04-29	AN
Scholz pledges further support for the pharmaceutical industry	04-25	DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	04-25	MT
AstraZeneca upbeat as cancer drugs underpin sales growth	04-25	AN
Daiichi Sankyo Company, Limited Announces Dividend for the Year Ended March 31, 2024, Payable on June 18, 2024 and Provides Dividend Guidance for Second Quarter of Fiscal Ending March 31, 2025	04-25	CI
Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025	04-25	CI
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	04-25	CI
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.	04-25	CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.	04-24	CI
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	04-10	MT
AstraZeneca hails neurological data for Ultomiris, Soliris	04-08	AN
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	04-05	CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	04-05	RE
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	04-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Highlights

Filters